CHRS Coherus BioSciences Inc.

Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022

Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8th, 2022. Starting at 5:00 p.m. Eastern Time on November 8, 2022, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. The press release with the third quarter 2022 financial results and related materials will be available at prior to the start of the conference call.

A replay of the webcast will be available on following the conclusion of the live conference call.

Conference Call Information

When: Tuesday, November 8th, 2022, starting at 5:00 p.m. Eastern Time

To access the conference call, please pre-register through the following link to receive dial-in information and personal PIN to access the live call:

Webcast:

Please dial-in 15 minutes early to ensure a timely connection to the call.

Coherus Contact Information:

Marek Ciszewski, SVP Investor Relations

Coherus Biosciences, Inc.





EN
01/11/2022

Underlying

CHRSCoherus BioSciences Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coherus BioSciences Inc.

 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus BioSciences Reports First Quarter 2025 Financial Results and P...

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update – Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million ...

May 12, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on following the conclusion of the live conference call. Conference Call Inf...

May 5, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus to Participate in Upcoming Investor Conferences

Coherus to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be webcasting its participation in the upcoming conferences: Citizens Life Science Conference in New York, NY on Thursday, May 8, 2025 at 9:00 a.m. Eastern Daylight Time / 6:00 a.m. Pacific Daylight Time – HCW BioConnect @ Nasdaq NYC 2025 in New York, NY on Tuesday, May 20, 2025 at 12:00 p.m. Eastern Daylight Time / 9:00 a.m. Pacific Daylight Time – TD Cowen 6th Annual Oncology Innovation S...

May 1, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expan...

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 – CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host ...

April 28, 2025 1 EN
 PRESS RELEASE
Free
CHRS Coherus BioScie...

Coherus Completes Strategic Transformation with Successful Divestiture...

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise  – $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts – – Coherus to focus exclusively on its innovative novel oncology programs including:– LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor;– Casdozokitug, a first-in-class interleukin-27 (IL-27) antagonist;– CHS-114, a highly selective CCR8 (chemokine receptor 8) antibody – REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Coherus BioS...

April 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch